Post-natal erythromycin exposure and risk of infantile hypertrophic pyloric stenosis: a systematic review and meta-analysis

Pediatric Surgery International

Volumn 32, Issue 12, 2016, Pages 1147-1152

  Murchison, L ^a,b   De Coppi, P ^a,b   Eaton, S ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

Erythromycin; Macrolide antibiotics; Pyloric stenosis

Indexed keywords

ERYTHROMYCIN; ANTIINFECTIVE AGENT;

ARTICLE; DISEASE ASSOCIATION; HUMAN; HYPERTROPHIC PYLORUS STENOSIS; INFANTILE HYPERTROPHIC PYLORIC STENOSIS; META ANALYSIS; PERINATAL DRUG EXPOSURE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; STUDY DESIGN; SYSTEMATIC REVIEW; TREATMENT DURATION; CHEMICALLY INDUCED; FEMALE; INFANT; MALE; NEWBORN; ODDS RATIO;

ANTI-BACTERIAL AGENTS; ERYTHROMYCIN; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; ODDS RATIO; PYLORIC STENOSIS, HYPERTROPHIC; RETROSPECTIVE STUDIES;

EID: 84988661120     PISSN: 01790358     EISSN: 14379813     Source Type: Journal    
DOI: 10.1007/s00383-016-3971-5     Document Type: Article

References (23)

1. Laffolie J, Turial S, Heckmann M, Zimmer KP, Schier F (2012) Decline in infantile hypertrophic pyloric stenosis in Germany in 2000–2008. Pediatrics 129:e901–e906. doi:10.1542/peds.2011-2845
2. Georgoula C, Gardiner M (2012) Pyloric stenosis a 100 years after Ramstedt. Arch Dis Child 97:741–745. doi:10.1136/archdischild-2011-301526
3. Krogh C, Fischer TK, Skotte L, Biggar RJ, Øyen N, Skytthe A, Goertz S, Christensen K, Wohlfahrt J, Melbye M (2010) Familial aggregation and heritability of pyloric stenosis. JAMA. 303(23):2393–2399. doi:10.1001/jama.2010.784
4. MacMahon B (2006) The continuing enigma of pyloric stenosis of infancy: a review. Epidemiology 17(2):195–201. doi:10.1097/01.ede.0000192032.83843.c9
5. Pedersen RN, Garne E, Loane M, Korsholm L, Husby S, EUROCAT Working Group (2008) Infantile hypertrophic pyloric stenosis: a comparative study of incidence and other epidemiological characteristics in seven European regions. J Matern Fetal Neonatal Med 21(9):599–604. doi:10.1080/14767050802214824
6. Maheshwai N (2007) Are young infants treated with erythromycin at risk for developing hypertrophic pyloric stenosis? Arch Dis Child 92:271–273. doi:10.1136/adc.2006.110007
7. Mavromati T, Papapanagioutou D, Bursinos B (1995) Gastroduodenal: prokinetic action of erythromycin on the operated stomach. Br J Surg 82:50
8. Ludvigsson JF, Lundholm C, Örtqvist AK, Almqvist C (2016) No association between macrolide treatment in infancy and later pyloric stenosis in Sweden. Eur J Epidemiol 31:331–332. doi:10.1007/s10654-015-0114-6
9. Ng PC, So KW, Fung KS, Lee CH, Fok TF, Wong E, Wong W, Cheung KL, Cheng AF (2001) Randomised controlled study or oral erythromycin for treatment of gastrointestinal dysmotility in preterm infants. Arch Dis Child Health Fetal Neonatal Ed 84:F177–F182
10. Cooper WO, Griffin MR, Arbogast P, Hickson GB, Gautam S, Ray WA (2002) Very early exposure to erythromycin and infantile hypertrophic pyloric stenosis. Arch Pediatr Adolesc Med 156(7):647–650
11. Eberly MD, Eide MB, Thompson JL, Nylund CM (2015) Azithromycin in early infancy and pyloric stenosis. Paediatrics 135(3):483–488. doi:10.1542/peds.2014-2026
12. Mahon BE, Rosenman MB, Kleiman MB (2001) Maternal and infant use of erythromycin and other macrolide antibiotics as risk factors for infantile hypertrophic pyloric stenosis. J Pediatr 139(3):380–384
13. Honein MA, Paulozzi LJ, Himelright IM, Lee B, Cragan JD, Patterson L, Correa A, Hall S, Erickson JD (1999) Infantile hypertrophic pyloric stenosis after pertussis prophylaxis with erythromycin: a case review and cohort study. Lancet 354(9196):2101–2105
14. Ericson JE, Arnold C, Cheeseman J, Cho J, Kaneko S, Wilson E, Clark RH, Benjamin DK Jr, Chu V, Smith PB, Hornik CP, Best Pharmaceuticals for Children Act-Pediatric Trials Network Administrative Core Committee (2015) Use and safety of erythromycin and metoclopramide in hospitalized infants. J Pediatr Gastroenterol Nutr. 61(3):334–339. doi:10.1097/MPG.0000000000000792
15. Lund M, Pasternak B, Davidsen RB, Feenstra B, Krogh C, Diaz LJ, Wohlfahrt J, Melbye M (2014) Use of macrolides in mother and child and risk of infantile hypertrophic pyloric stenosis: nationwide cohort study. BMJ 348:g1908. doi:10.1136/bmj.g1908
16. Mohammadizadeh M, Ghazinour M, Iranpour R (2010) Efficacy of prophylactic oral erythromycin to improve enteral feeding tolerance in preterm infants: a randomised controlled study. Singapore Med J. 51(12):952–956
17. Rosenman MB, Mahon BE, Downs SM, Kleiman MB (2003) Oral erythromycin prophylaxis vs watchful waiting in caring for newborns exposed to Chlamydia trachomatis. Arch Pediatr Adolesc Med 157(6):565–571. doi:10.1001/archpedi.157.6.565
18. Sørensen HT, Skriver MV, Pedersen L, Larsen H, Ebbesen F, Schønheyder HC (2003) Risk of infantile hypertrophic pyloric stenosis after maternal postnatal use of macrolides. Scand J Infect Dis 35(2):104–106. doi:10.1080/0036554021000027010
19. Goldstein LH, Berlin M, Tsur L, Bortnik O, Binyamini L, Berkovitch M (2009) The safety of macrolides during lactation. Breastfeed Med 4(4):197–200. doi:10.1089/bfm.2008.0135
20. Salman S, Rogerson SJ, Kose K, Griffin S, Gomorai S, Baiwog F, Winmai J, Kandai J, Karunajeewa HA, O’Halloran SJ, Siba P, Ilett KF, Mueller I, Davis TM (2010) Pharmacokinetic properties of azithromycin in pregnancy. Antimicrob Agents Chemother 54(1):360–366. doi:10.1128/AAC.00771-09
21. Källén BA, Otterblad Olausson P (2005) Danielsson BR (2005) Is erythromycin therapy teratogenic in humans? Reprod Toxicol 20(2):209–214. doi:10.1016/j.reprotox.2005.01.010
22. Lin KJ, Mitchell AA, Yau WP, Louik C, Hernández-Díaz S (2013) Safety of macrolides during pregnancy. Am J Obstet Gynecol 208(3):221.e1–8. doi:10.1016/j.ajog.2012.12.023
23. Louik C, Werler MM, Mitchell AA (2002) Erythromycin use during pregnancy in relation to pyloric stenosis. Am J Obstet Gynecol 186(2):288–290